2023-05-11 / 117 reading

About CPHI  CHINA 2023

China has become the world’s largest producer of APIs. It is reported that in 2010, China’s raw material drug exports emerged from the impact of the financial crisis and achieved recovery growth, with exports reaching 20.301 billion US dollars, a year-on-year increase of 26.19%; Maintain stable growth in export volume; The average export price has rebounded by 2.27%. The proportion of raw material drug exports to pharmaceutical product exports is 51.09%.

Chinese pharmaceutical companies are fully integrating into the global pharmaceutical market in a new form, unprecedented scale, and speed. At the same time, in the process of international growth, there are also risks and challenges, such as regulatory thresholds and compliance requirements in the international market, international commercial defaults, international team collaboration, differentiated markets, and so on.

In the new era, China’s pharmaceutical globalization has shifted from high-speed to high-quality. Whether it is upgrading and developing characteristic raw materials, or transforming and expanding pharmaceutical business, the internal driving force comes from innovation. The CPHI forum covers multiple fields such as the development status and policy direction of the pharmaceutical industry, technological innovation and product registration, international trade, etc. From a global strategic perspective, it keenly observes and deeply analyzes the new environment and situation of the development of the pharmaceutical industry at home and abroad, providing a high-level communication platform for domestic and foreign pharmaceutical entrepreneurs, industry experts, and relevant government departments.

Since 2014, with the strong support of domestic and foreign regulatory agencies and pharmacopoeia agencies, including NMPA, FDA, EDQM, MHRA, PMDA, WHO, ChP, USP, BP, EP, JP, etc., activities have focused on updating regulatory policies and drug standards, and interpreting and analyzing future trends.

The CHPI exchange will invite senior experts to provide authoritative analysis on the registration change management of pharmaceutical excipients under the related review and approval system. At the same time, representatives from leading pharmaceutical excipient companies will also discuss with the attending guests how to upgrade pharmaceutical formulations and dosage forms through technological application.

Shanghai Kekai Biotechnology Co., Ltd. is dedicated to the research and production of biological enzyme reagents, recombinant proteins, chemical reagents and cell growth factors. We are willing to work with you to serve pharmaceutical companies and scientific experimental units around the world, and contribute to bioengineering.